Go Deep
Stella Pharma Corporation
Stella Pharma Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,500 | -16.5 | 4.60 | 0.28 | 248.80 |
Stella Pharma Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 92,397,000.0 | 61,598,000.0 | 61,598,000.0 | 107,796,000.0 |
| Net Profit | -228,827,000.0 | -268,774,000.0 | -204,228,000.0 | -151,235,000.0 |
| EPS | -6.5 | — | — | — |
Stella Pharma Corporation Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 323,389,000.0 | 961,058,000.0 | 269,491,000.0 | 229,067,000.0 | — |
| Net Profit | -780,917,000.0 | -140,811,000.0 | -763,749,000.0 | -778,824,000.0 | — |
| EPS | -22.9 | -4.2 | -24.7 | -27.0 | — |
Stella Pharma Corporation Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 4,486,694,000.0 | 5,417,104,000.0 | 3,820,622,000.0 | 4,329,053,000.0 | — |
| Total Liabilities | 2,060,126,000.0 | 2,209,618,000.0 | 1,443,610,000.0 | 1,576,552,000.0 | — |
| Total Equity | 2,426,568,000.0 | 3,207,486,000.0 | 2,377,012,000.0 | 2,752,501,000.0 | — |
Owes vs Owns
Stella Pharma Corporation owed ¥0.40 for every ¥1 it owned in Jun 2026, up from ¥0.36 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.40× | 0.46× | 0.41× | 0.38× | 0.36× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Stella Pharma Corporation Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 62.9%Receivables 1.5%Inventory 28.9%Fixed assets (tangible) 1.0%Intangible assets 1.0%Other assets 4.7%
How it's funded — Mar 2026
Short-term debt 3.5%Long-term debt 13.1%Other liabilities 29.3%Shareholders' equity 54.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,823.0 | 3,206.5 | 2,353.6 | 2,710.3 |
| Receivables | 67.8 | 714.7 | 76.2 | 59.3 |
| Inventory | 1,295.8 | 1,230.7 | 1,116.3 | 940.6 |
| Fixed assets (tangible) | 47.1 | 66.5 | 81.5 | 102.9 |
| Intangible assets | 42.7 | 49.3 | 52.5 | 61.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 302.7 |
| Other assets | 210.3 | 149.5 | 140.4 | 151.6 |
| Liabilities & equity | ||||
| Short-term debt | 158.6 | 158.6 | 160.0 | 160.0 |
| Long-term debt | 588.5 | 608.1 | 773.3 | 933.3 |
| Payables | 0.0 | 22.7 | 75.7 | 49.1 |
| Other liabilities | 1,313.0 | 1,420.1 | 434.6 | 434.2 |
| Shareholders' equity | 2,426.6 | 3,207.5 | 2,377.0 | 2,752.5 |
| Net tangible assets | 2,383.8 | 3,158.2 | 2,324.5 | 2,690.8 |
Stella Pharma Corporation Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -334,514,000.0 | 140,408,000.0 | -876,837,000.0 | -827,669,000.0 | — |
| Investing Activities | -15,671,000.0 | 287,576,000.0 | -9,010,000.0 | -29,925,000.0 | — |
| Financing Activities | -33,279,000.0 | 721,253,000.0 | 228,353,000.0 | 291,819,000.0 | — |